Healthcare Policy Lobbyist (Biotech)

EQL Tech•Washington, DC

1d•$200,000 - $250,000•Remote

About The Position

The Clinical Trial Abundance Initiative aims to reform federal policy and law governing clinical trials to make them faster, cheaper, and simpler to conduct. This new, founder-led effort, backed by leading science philanthropies, seeks to leverage the 2027 reauthorization of the Prescription Drug User Fee Act (PDUFA) to drive significant reform. The initiative will draw on successful international models to create a more efficient system for clinical trials. This role is focused on policy and law reform, not on the operational aspects of running trials or issues of access, diversity, inclusion, or equity. The goal is to increase the speed, reduce the cost, and enhance the abundance of clinical trials by reforming the governing system.

Requirements

Deep credibility in biotech, life sciences, or FDA / clinical-trial policy — this is a subject-matter role, not a generalist government-affairs one
A track record of being taken seriously by senior, varied stakeholders: Hill offices, agencies, industry executives, investors, and researchers alike
Evidence that you can build something durable, not only win a near-term legislative fight — coalition-building, institution-building, or genuine 0→1 experience
Fluent in the case for reform that expands what's possible — cutting the friction, cost, and time between good science and the patients who need it

Nice To Haves

Direct experience with PDUFA, user-fee reauthorizations, or FDA review-pathway reform
Familiarity with international regulatory models (Australia, UK, EU)
An existing network spanning biotech, investors, research, and DC policy

Responsibilities

Serve as the initiative's lead voice with legislators, congressional staff, and agency officials, and with health-system and industry leaders — building credibility and trust across a wide and varied set of stakeholders
Shape a substantive agenda to reform the policy and law around the cost, speed, and complexity of trials, and drive it into the PDUFA 2027 reauthorization and its implementation
Design and build the coalition — recruiting and aligning companies, investors, research and patient organizations, and allied policymakers into a lasting interest group
Translate the scientific and regulatory case for reform into arguments that move different audiences, in partnership with the Chief Science Officer
Set the initiative's strategy for the years beyond 2027, when the work is field-building rather than chasing a single deadline